Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000245
UniProt IDP55957
Primary gene name(s)BID
Synonym gene name(s)unknown
Protein nameBH3-interacting domain death agonist
Protein functionThe major proteolytic product p15 BID allows the release of cytochrome c, By similarity. Isoform 1, isoform 2 and isoform 4 induce ICE-like proteases and apoptosis. Isoform 3 does not induce apoptosis. Counters the protective effect of Bcl-2. {ECO:0000250, ECO:0000269|PubMed:14583606}.
Subcellular locationCytoplasm {ECO:0000250}. Mitochondrion membrane {ECO:0000250}. Note=When uncleaved, it is predominantly cytoplasmic. {ECO:0000269|PubMed:14583606}.;
SUBCELLULAR LOCATION: BH3-interacting domain death agonist p15: Mitochondrion membrane {ECO:0000250}. Note=Translocates to mitochondria as an integral membrane protein. {ECO:0000250}.;
SUBCELLULAR LOCATION: BH3-interacting domain death agonist p13: Mitochondrion membrane {ECO:0000250}. Note=Associated with the mitochondrial membrane. {ECO:0000250}.;
SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.;
SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.;
SUBCELLULAR LOCATION: Isoform 2: Mitochondrion membrane. Note=A significant proportion of isoform 2 localizes to mitochondria, it may be cleaved constitutively.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P55957
Gene Ontology
(Biological Process)
Complete annatation
activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919];
apoptotic mitochondrial changes [GO:0008637];
brain development [GO:0007420];
establishment of protein localization to membrane [GO:0090150];
extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625];
glial cell apoptotic process [GO:0034349];
hepatocyte apoptotic process [GO:0097284];
mitochondrial outer membrane permeabilization [GO:0097345];
neuron apoptotic process [GO:0051402];
positive regulation of apoptotic process [GO:0043065];
positive regulation of extrinsic apoptotic signaling pathway [GO:2001238];
positive regulation of intrinsic apoptotic signaling pathway [GO:2001244];
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901030];
positive regulation of protein homooligomerization [GO:0032464];
positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [GO:1900740];
positive regulation of protein oligomerization [GO:0032461];
positive regulation of release of cytochrome c from mitochondria [GO:0090200];
protein homooligomerization [GO:0051260];
protein targeting to mitochondrion [GO:0006626];
regulation of apoptotic process [GO:0042981];
regulation of cell proliferation [GO:0042127];
regulation of G1/S transition of mitotic cell cycle [GO:2000045];
release of cytochrome c from mitochondria [GO:0001836];
response to estradiol [GO:0032355];
signal transduction in response to DNA damage [GO:0042770]
Gene Ontology
(Molecular Function)
Complete annatation
death receptor binding [GO:0005123]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
extracellular exosome [GO:0070062];
integral component of mitochondrial membrane [GO:0032592];
membrane [GO:0016020];
mitochondrial outer membrane [GO:0005741];
mitochondrion [GO:0005739]
Protein-protein interaction107106
Phylogenetic treeP55957
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-1.026820588988930.0569893638820060.111406445191906
AZA vs. DISU-0.009962255389693680.9688506554717140.997285288974472
AZA vs. IL70.2571924917765550.1876413563287190.952505417553304
AZA vs. SAHA-0.6392932795317150.01020415615365420.0989179741866133
DISU vs. CD31.004041884758270.0651400840513040.133467667118303
DISU vs. IL70.2581589718577330.3092458518332970.692938110906189
DISU vs. SAHA-0.6278841183354950.03409005513425090.222990981305684
DMSO vs. AZA0.007793657771526360.9637133409675891
DMSO vs. CD31.019755172636350.05850793018399680.109902988556348
DMSO vs. DISU0.01491905036691590.9516439574757420.993447978824122
DMSO vs. IL70.2570891426255330.1592407406496730.664973452989978
DMSO vs. SAHA-0.6527488281178780.006625826447694940.0679304968661295
HIV vs. Mock in Activation-0.1459557947863090.8999399256027740.999983755607037
HIV vs. Mock in Latency-0.1104272409132630.5134573004745320.999834320637052
IL7 vs. CD31.291724337771990.01726276553092860.0466565173441808
SAHA vs. CD30.3623768184772920.5103262445155690.618664347586648
SAHA vs. IL7-0.9003936960015530.0002922724794288680.00455606551697079
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
1.9 3.65E-05 1.3 0.010049428 1.5 0.005251678
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.538672 0.0107117
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.028 1.081 1.011 1.064 1.091
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1ZY3 NMR - B=82-101.
2BID NMR - A=1-195.
2KBW NMR - B=76-106.
2M5B NMR - B=80-101.
2M5I NMR - A=61-195.
4BD2 X-ray 2.2Å C=76-109.
4QVE X-ray 2.0Å B=76-109.
4ZEQ X-ray 1.8Å B=79-104.
4ZIG X-ray 2.2Å B=79-98.
4ZII X-ray 2.1Å C=76-109.
5AJJ X-ray 1.7Å B=79-112.
5C3F X-ray 1.4Å B=80-101.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Vpr upregulates 20801175
Tat upregulates 23364796
retropepsin induces cleavage of 12404116
Vpr induces cleavage of 20404718
Envelope surface glycoprotein gp120 induces cleavage of 17488272
Tat interacts with 23364796

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01524 Platinum drug resistance - Homo sapiens (human)
hsa04071 Sphingolipid signaling pathway - Homo sapiens (human)
hsa04115 p53 signaling pathway - Homo sapiens (human)
hsa04210 Apoptosis - Homo sapiens (human)
hsa04215 Apoptosis - multiple species - Homo sapiens (human)
hsa04650 Natural killer cell mediated cytotoxicity - Homo sapiens (human)
hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human)
hsa05010 Alzheimer's disease - Homo sapiens (human)
hsa05014 Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human)
hsa05152 Tuberculosis - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05416 Viral myocarditis - Homo sapiens (human)